Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared on X:
“New era for HER2-mutant lung cancer!
Zongertinib delivered a 71% response rate, 12.4 months median PFS, and low-grade toxicity. No ILD reported.
Precision hitting its mark!”
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
Authors: John V. Heymach et al.
Read Also: New Paper Alert: Zongertinib in Previously Treated HER2-Mutant NSCLC. Beamion LUNG-1 Study Results